|
ARBs |
Half-life (h) |
Tmax (h) |
Bio-availability |
Route of elimination: |
Food Interaction |
|
Losartan* |
2 |
1–1.5 |
33% |
35% R; 60% B |
Yes |
|
Candesartan cilexetil |
9 |
2-5 |
42% |
33% R; 67% B |
No |
|
Eprosartan |
5–9 |
1–3 |
63% |
7% R; 90% B |
Yes |
|
Irbesartan |
11–15 |
1.3–3 |
60–80% |
20% R; 80% B |
No |
|
Telmisartan |
24 |
0.5–1 |
43% |
<1% R; >97% B |
No |
|
Valsartan |
6 |
2–4 |
23% |
13% R; 83% B |
Yes |
|
Olmesartan medoxomil |
12–14 |
1.7–2.5 |
26% |
35–50%R; 50–65% B |
No |
|
Azilsartan medoxomil |
12 |
1.5–3 |
60% |
42% urine; 55% B |
No |
*Losartan is converted to EXP-3174 with terminal half-life of 6–9 hours and Tmax of 4–6 hours.
|
ARBs |
Starting dose (mg/day) |
Maximum dose (mg/day) |
Dosing interval |
Other Indications Approved Outside of Hypertension |
|
Losartan |
50 |
100 |
Once a day or twice a day |
Diabetic nephropathy when serum creatinine is increased and proteinuria present in patients with hypertension and type 2 diabetes; Stroke reduction in patients with hypertension and left ventricular hypertrophy (non-black only) |
|
Candesartan cilexetil |
16 |
32 |
Once a day or twice a day |
Treatment of heart failure (NYHA Classes II–IV) |
|
Eprosartan |
600 |
800 |
Once a day or twice a day |
None |
|
Irbesartan |
150 |
300 |
Once a day |
Diabetic nephropathy when serum creatinine is increased and proteinuria present in patients with hypertension and type 2 diabetes |
|
Telmisartan |
40 |
80 |
Once a day |
Cardiovascular risk reduction in patients unable to take ACE inhibitors |
|
Valsartan |
80 or 160 |
320 |
Once a day |
Treatment of heart failure (NYHA Classes II–IV); Reduction of CV mortality in clinically stable patients with left ventricular failure or dysfunction following myocardial infarction. |
|
Olmesartan medoxomil |
20 |
40 |
Once a day |
None |
|
Azilsartan medoxomil |
40 or 80 |
80 |
Once a day |
None |
- Abraham HM, White CM, White WB. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf. 2015 Jan;38(1):33-54. [Medline]
- Makani H, Bangalore S, Supariwala A, Romero J, Argulian E, Messerli FH. Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis. Eur Heart J. 2014 Jul;35(26):1732-42. [Medline]
- Dézsi CA. The Different Therapeutic Choices with ARBs. Which One to Give? When? Why? Am J Cardiovasc Drugs. 2016 Aug;16(4):255-66. [Medline]
